Skip to content

Trial Summary

Multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl.

Acronym:

ANAM-17-21

ACTRN/NCT /ethics:

NCT03743064

Scientific title:

A phase III, randomised, double-blind, placebo-controlled, mutli-centre study to evaluate the efficacy and safety of anamorelin HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLC.

Sponsor / Cooperative group:

Helsinn Healthcare SA

Trial & Patient Characteristics

Cancer TypeLung & mesothelioma
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexBoth
Tumour Stream NSCLC
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2018-12-18
Anticipated End Date2021-07-01

Participating Hospitals

HospitalCalvary Central Districts Hospital
Clinical Trial CoordinatorJulie Rowe
Emailjulie.rowe@calvarycare.org.au
Phone08 8239 9536
Principal InvestigatorDr Vineet Kwatra
Recruitment StatusRecruiting